TABLE 2.
Mean (SD) Percent Change from Baseline in Total-c, HDL-c, LDL-c, and Triglycerides Over Time in the OLE Study
| Visit (mo) |
Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | |||
|---|---|---|---|---|---|
| n | % (SD) | n | % (SD) | ||
| Total-c | 12 | 164 | –1.6 (14.1) | 480 | 11.4 (21.1) |
| 24 | 139 | –1.5 (15.6) | 399 | 12.2 (21.4) | |
| 36 | 121 | –2.4 (16.4) | 328 | 12.8 (23.2) | |
| 48 | 52 | –5.1 (18.2) | 213 | 10.4 (21.6) | |
| HDL-c | 12 | 164 | –2.0 (17.1) | 479 | 11.3 (27.4) |
| 24 | 139 | 1.1 (15.4) | 399 | 12.2 (27.2) | |
| 36 | 121 | –2.5 (14.6) | 328 | 13.6 (27.7) | |
| 48 | 53 | –5.1 (11.8) | 213 | 10.9 (28.7) | |
| LDL-c | 12 | 161 | –0.1 (19.9) | 475 | 14.4 (30.0) |
| 24 | 135 | –2.8 (23.9) | 397 | 14.9 (31.0) | |
| 36 | 119 | –1.3 (24.0) | 326 | 14.5 (33.3) | |
| 48 | 51 | –5.1 (26.2) | 213 | 12.4 (32.3) | |
| Triglycerides | 12 | 164 | 6.1 (38.5) | 479 | 10.6 (49.8) |
| 24 | 139 | 15.4 (52.8) | 399 | 13.8 (55.4) | |
| 36 | 120 | 12.2 (47.0) | 328 | 19.6 (65.8) | |
| 48 | 52 | 16.0 (43.2) | 213 | 18.3 (64.1) |
Abbreviations: BID, twice daily; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; n, number of patients with non-missing data; OLE, open-label, long-term extension; SD, standard deviation; total-c, total cholesterol.